[ad_1]
The entire domain of messenger ARNs has attracted billions of dollars from public and private investors, who have bet on the prospect of entering the ground floor. And this morning, Moderna, one of the Boston-based leaders, wants to show you some extra cards to prove you're really in the game.
The whole hand, of course, has not been treated yet. And we do not know who will walk with one part of the pot. But all the cards at this stage – especially after being accused of keeping his game under lock and key – will attract the attention of many very wary and wired observers.
"In terms of complexity and unmet need," says Tal Zaks, Chief Medical Officer, "This is the pinnacle of what we have accomplished."
Moderna has two Phase I studies that he wants to talk about now.
Continue reading endpoints with a free subscription
Instantly discover this story and join more than 59,700 biopharmaceutical professionals who read endpoints daily – for free.
[ad_2]
Source link